Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Respiration ; 97(5): 472-475, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30928982

RESUMEN

GATA2 deficiency is characterized by monocytopenia, deficiency of dendritic cells, and a variable degree of lymphocytopenia affecting B cells and NK cells, leading to an enhanced risk of mycobacterial, viral, and fungal infections. Here we present a patient with a heterozygous intronic GATA2 mutation who acquired a fatal disseminated mycosis due to the black yeast-like fungus Arthrocladium fulminans following an infection with Mycobacterium sherrisii. This case illustrates that in patients with severe uncommon infections, immunodeficiency syndromes must be ruled out.


Asunto(s)
Antifúngicos/administración & dosificación , Hongos , Deficiencia GATA2 , Síndromes de Inmunodeficiencia , Infecciones Fúngicas Invasoras , Pulmón , Encéfalo/diagnóstico por imagen , Broncoscopía/métodos , Deterioro Clínico , Resultado Fatal , Femenino , Hongos/aislamiento & purificación , Hongos/patogenicidad , Deficiencia GATA2/diagnóstico , Deficiencia GATA2/inmunología , Deficiencia GATA2/fisiopatología , Deficiencia GATA2/terapia , Factor de Transcripción GATA2/genética , Humanos , Síndromes de Inmunodeficiencia/sangre , Síndromes de Inmunodeficiencia/diagnóstico , Síndromes de Inmunodeficiencia/terapia , Infecciones Fúngicas Invasoras/diagnóstico , Infecciones Fúngicas Invasoras/inmunología , Infecciones Fúngicas Invasoras/fisiopatología , Infecciones Fúngicas Invasoras/terapia , Pulmón/diagnóstico por imagen , Pulmón/microbiología , Mutación , Tomografía Computarizada por Rayos X/métodos , Adulto Joven
2.
Int Ophthalmol ; 39(6): 1379-1385, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29705891

RESUMEN

PURPOSE: To report on a wearer of rigid gas-permeable contact lenses with a keratomycosis due to Tintelnotia-a new genus of Phaeosphaeriaceae-treated with terbinafine and polyhexamethylene biguanide. METHODS: Chart review of a patient with fungal keratitis treated additionally with systemic and topical terbinafine 0.25% after symptoms increased under conventional antimycotic therapy with voriconazole. Antifungal susceptibility had been tested in vitro. RESULTS: After starting an additional treatment with systemic and topical terbinafine, the severe corneal infection was sufficiently resolved. The drug was well tolerated without any neurological, dermatological or gastroenterological problems. Terbinafine revealed a marked in vitro antifungal activity of 0.12 µg/ml. The fungus was identified as Tintelnotia destructans. CONCLUSIONS: Terbinafine might be considered as a therapeutic option in severe cases of fungal keratitis refractory to common antifungal therapy.


Asunto(s)
Antifúngicos/uso terapéutico , Ascomicetos/aislamiento & purificación , Biguanidas/uso terapéutico , Desinfectantes/uso terapéutico , Queratitis/microbiología , Terbinafina/uso terapéutico , Adulto , Humanos
3.
Artículo en Inglés | MEDLINE | ID: mdl-29891611

RESUMEN

Scedosporium spp. cause infections (scedosporiosis) in both immunocompetent and immunocompromised individuals and may persistently colonize the respiratory tract in patients with cystic fibrosis (CF). They are less susceptible against azoles than are other molds, such as Aspergillus spp., suggesting the presence of resistance mechanisms. It can be hypothesized that the decreased susceptibility of Scedosporium spp. to azoles is also CYP51 dependent. Analysis of the Scedosporium apiospermum and Scedosporiumaurantiacum genomes revealed one CYP51 gene encoding the 14-α-lanosterol demethylase. This gene from 159 clinical or environmental Scedosporium isolates and three Lomentospora prolificans isolates has been sequenced and analyzed. The Scedosporium CYP51 protein clustered with the group of known CYP51B orthologues and showed species-specific polymorphisms. A tandem repeat in the 5' upstream region of Scedosporium CYP51 like that in Aspergillus fumigatus could not be detected. Species-specific amino acid alterations in CYP51 of Scedosporium boydii, Scedosporiumellipsoideum, Scedosporium dehoogii, and Scedosporiumminutisporum isolates were located at positions that have not been described as having an impact on azole susceptibility. In contrast, two of the three Sapiospermum-specific amino acid changes (Y136F and G464S) corresponded to respective mutations in A. fumigatus CYP51A at amino acid positions 121 and 448 (Y121F and G448S, respectively) that had been linked to azole resistance.


Asunto(s)
Scedosporium/efectos de los fármacos , Scedosporium/genética , Esterol 14-Desmetilasa/genética , Antifúngicos/farmacología , Azoles/farmacología , Farmacorresistencia Fúngica/genética , Proteínas Fúngicas/genética , Mutación
4.
Med Mycol ; 56(suppl_1): 102-125, 2018 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-29538735

RESUMEN

Species of Scedosporium and Lomentospora are considered as emerging opportunists, affecting immunosuppressed and otherwise debilitated patients, although classically they are known from causing trauma-associated infections in healthy individuals. Clinical manifestations range from local infection to pulmonary colonization and severe invasive disease, in which mortality rates may be over 80%. These unacceptably high rates are due to the clinical status of patients, diagnostic difficulties, and to intrinsic antifungal resistance of these fungi. In consequence, several consortia have been founded to increase research efforts on these orphan fungi. The current review presents recent findings and summarizes the most relevant points, including the Scedosporium/Lomentospora taxonomy, environmental distribution, epidemiology, pathology, virulence factors, immunology, diagnostic methods, and therapeutic strategies.


Asunto(s)
Antifúngicos/uso terapéutico , Ascomicetos/fisiología , Farmacorresistencia Fúngica Múltiple/genética , Micosis/microbiología , Scedosporium/fisiología , Antifúngicos/farmacología , Ascomicetos/clasificación , Ascomicetos/efectos de los fármacos , Ascomicetos/genética , Terapia Combinada , Ecología , Interacciones Huésped-Patógeno/inmunología , Humanos , Huésped Inmunocomprometido , Tipificación Molecular , Micosis/diagnóstico , Micosis/patología , Micosis/terapia , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/microbiología , Infecciones Oportunistas/patología , Infecciones Oportunistas/terapia , Scedosporium/clasificación , Scedosporium/efectos de los fármacos , Scedosporium/genética , Procedimientos Quirúrgicos Operativos , Factores de Virulencia
5.
Fungal Genet Biol ; 87: 22-9, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26768709

RESUMEN

Cryptococcus neoformans var. neoformans (serotype D) represents about 30% of the clinical isolates in Europe and is present less frequently in the other continents. It is the prevalent etiological agent in primary cutaneous cryptococcosis as well as in cryptococcal skin lesions of disseminated cryptococcosis. Very little is known about the genotypic diversity of this Cryptococcus subtype. The aim of this study was to investigate the genotypic diversity among a set of clinical and environmental C. neoformans var. neoformans isolates and to evaluate the relationship between genotypes, geographical origin and clinical manifestations. A total of 83 globally collected C. neoformans var. neoformans isolates from Italy, Germany, France, Belgium, Denmark, Greece, Turkey, Thailand, Japan, Colombia, and the USA, recovered from different sources (primary and secondary cutaneous cryptococcosis, disseminated cryptococcosis, the environment, and animals), were included in the study. All isolates were confirmed to belong to genotype VNIV by molecular typing and they were further investigated by MLST analysis. Maximum likelihood phylogenetic as well as network analysis strongly suggested the existence of a recombinant rather than a clonal population structure. Geographical origin and source of isolation were not correlated with a specific MLST genotype. The comparison with a set of outgroup C. neoformans var. grubii isolates provided clear evidence that the two varieties have different population structures.


Asunto(s)
Criptococosis/microbiología , Cryptococcus neoformans/clasificación , Variación Genética , Genotipo , Tipificación de Secuencias Multilocus , Técnicas de Tipificación Micológica , Recombinación Genética , Américas , Asia , Cryptococcus neoformans/genética , Cryptococcus neoformans/aislamiento & purificación , Europa (Continente) , Filogeografía
6.
Pediatr Allergy Immunol ; 27(6): 597-603, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27145047

RESUMEN

BACKGROUND: Late diagnosis of allergic bronchopulmonary aspergillosis (ABPA) is associated with significant lung function decline and morbidity in cystic fibrosis (CF). The association of ABPA and domestic pet ownership in patients with CF has not been elucidated yet. Our objective was to determine the association of ABPA with pet ownership in patients with CF. METHODS: Clinical and microbiological data from certified local patient registry were analyzed for 109 patients with CF aged 1-64 years: 55 pet owner and 54 non-pet owners. The primary outcome of the retrospective observational study was the occurrence of ABPA in pet owners and non-pet owners with CF. The free statistical software R was utilized to investigate logistic regression models for association factors. RESULTS: Of the 109 patients included in the study, 61 (56%) were female. The mean age of the total group was 25.4 ± 13.2 years. Adjusted analysis revealed that ABPA (OR 5.0227, 95% CI: 1.182-21.340, p = 0.029) was associated with pet ownership in patients with CF. Furthermore, ABPA in pet owners with CF was associated with an increased number of exacerbations (OR 6.446, 95% CI: 1.057-39.328, p = 0.043). Other outcomes did not significantly differ. CONCLUSION: Owning a pet was associated with ABPA in patients with CF. Future prospective multicenter longitudinal studies are needed to investigate chronological causality between pet ownership, ABPA development, and pulmonary exacerbations and to determine whether these estimates are generalizable for ABPA susceptible patients beyond CF (asthma, bronchiectasis).


Asunto(s)
Aspergilosis Broncopulmonar Alérgica/epidemiología , Fibrosis Quística/epidemiología , Mascotas , Adolescente , Adulto , Alérgenos/inmunología , Animales , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Alemania/epidemiología , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
7.
J Clin Microbiol ; 53(4): 1056-62, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25297326

RESUMEN

Recent changes in the Fungal Code of Nomenclature and developments in molecular phylogeny are about to lead to dramatic changes in the naming of medically important molds and yeasts. In this article, we present a widely supported and simple proposal to prevent unnecessary nomenclatural instability.


Asunto(s)
Micosis/microbiología , Hongos/clasificación , Humanos , Infectología , Micología , Terminología como Asunto
8.
Int J Med Microbiol ; 305(7): 724-8, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26330287

RESUMEN

Scedosporiosis is a rare, but often fatal mycotic infection occurring in immunosuppressed as well as in immunocompetent patients. Over a period of 14 months, Scedosporium boydii isolates were sent to our reference laboratory from six immunocompetent patients treated at a single hospital in Germany. In analogy to the EORTC/MSG criteria, four patients were classified as proven invasive scedosporiosis cases, and two patients as probable or possible cases. Of note, in five patients scedosporiosis was diagnosed between 1 and 14 months (median 5.0 months) after cardiac surgery. Despite antimycotic treatment two patients died, and three were lost for long-term follow-up. All clinical S. boydii isolates were characterized by molecular analysis using multilocus sequence typing (MLST). An identical MLST type was found in five patients who had been treated in the surgery unit, suggesting a link between these infections. The source of S. boydii has not been identified. Within an observation period of 2 years before and after this cluster of infections no further cases of scedosporiosis were reported from this hospital.


Asunto(s)
Análisis por Conglomerados , Infección Hospitalaria/epidemiología , Micosis/epidemiología , Scedosporium/clasificación , Scedosporium/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/uso terapéutico , Niño , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Femenino , Genotipo , Alemania/epidemiología , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Epidemiología Molecular , Tipificación de Secuencias Multilocus , Micosis/tratamiento farmacológico , Micosis/microbiología , Scedosporium/aislamiento & purificación , Análisis de Supervivencia , Adulto Joven
9.
Int J Med Microbiol ; 305(7): 719-23, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26341329

RESUMEN

The fungal pathogen Cryptococcus gattii was considered to be restricted to tropic and sub- tropic regions. A recent outbreak in North America due to isolates belonging to molecular type VG II, affecting mostly non-immunocompromised hosts, documented the potential public health impact of this fungal pathogen also in temperate regions. Surveillance of these infections in Germany is challenging, as cryptococcosis is not notifiable and often C. gattii is diagnostically not distinguished from the more prevalent Cryptococcus neoformans. We used hospital discharge data and identified cryptococcal isolates received by the German cryptococcosis reference laboratory at the species level to gain insights into the epidemiology of C. gattii-infections in Germany between 2004 and 2013. Between 49 and 60 (Median 57) hospitalizations for cryptococcosis are documented per year. Between 5 and 28 (Median 14) isolates were received at the reference laboratory per year. Among 155 single patient isolates, four C. gattii (3%) of the molecular types VGI and VG III were identified from patients with meningoencephalitis, including one interspecies hybrid. Patient histories and molecular typing suggest that half of the infections were acquired abroad. Only one patient survived the infection. C. gattii remains rarely identified as agent of cryptococcosis in Germany but underestimation is likely. Definition of environmental niches occupied by C. gattii in Germany may help to assess the associated risk of infection and prevent this deadly fungal infection.


Asunto(s)
Criptococosis/epidemiología , Criptococosis/microbiología , Cryptococcus gattii/aislamiento & purificación , Adulto , Cryptococcus gattii/clasificación , Cryptococcus gattii/genética , Genotipo , Alemania/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia
10.
Med Mycol ; 53(2): 132-44, 2015 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-25550386

RESUMEN

In a retrospective study, we investigated 52 formalin-fixed, paraffin-embedded (FFPE) samples from cats with histologically confirmed cutaneous and subcutaneous mycoses to determine if the pathogens could be identified by molecular methods. Aim of the study was to obtain a deep understanding of the spectrum of infectious agents, which, as we hypothesized, was not available by histopathology alone. Detection of feline and fungal DNA was achieved in 92.3% and 94.2% of the samples, respectively. Most of the subcutaneous infections in cats were caused by Alternaria spp. (63.5%), followed by Cryptococcus neoformans (7.7%), Histoplasma capsulatum (5.8%), Sporothrix spp. (3.8%), Aspergillus vitricola, Aureobasidium pullulans, Exophiala attenuata, Fusarium oxysporum, Lecythophora cateniformis, Microsporum canis, and Phialophora sp. (1.9% each). The results from molecular identification indicate that correct identifications of the fungal pathogens by histology alone were rarely possible. The spectrum of fungal pathogens identified after DNA extraction from FFPE samples was much broader than that expected by classical histopathology. This was especially noted in alternariosis in that the micromorphological pattern in tissue was misleading and could be confused with that of cryptococcosis. Due to different susceptibilities to antifungal agents, it is important to arrive at a definitive diagnosis, which might be possible by examination of the fungus recovered in culture and/or molecular methods, in addition to the histopathologic techniques.


Asunto(s)
Enfermedades de los Gatos/diagnóstico , Dermatomicosis/diagnóstico , Hongos/clasificación , Hongos/aislamiento & purificación , Técnicas de Diagnóstico Molecular/métodos , Patología Molecular/métodos , Animales , Enfermedades de los Gatos/microbiología , Gatos , Dermatomicosis/microbiología , Hongos/genética , Estudios Retrospectivos
11.
Med Mycol ; 53(8): 874-9, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26337090

RESUMEN

The detection of cryptococcal antigen by latex agglutination tests (LATs), enzyme-linked immunoassays (ELISA), or lateral flow assay (LFA) is an important tool for diagnosis of a Cryptococcus infection. Cerebrospinal fluid and/or serum samples of 10 patients with cryptococcosis due to Cryptococcus gattii or a hybrid of Cryptococcus neoformans and C. gattii were examined by three LATs (the IMMY Latex-Crypto(®) test, the Pastorex(TM) Crypto Plus, and the Remel Cryptococcus Antigen Test Kit) and the LFA made by Immuno-Mycologics. LATs based on monoclonal antibodies (mAbs) like the Pastorex(TM) Crypto Plus or the Remel Cryptococcus Antigen Test Kit turned out to have an insufficient sensitivity to detect four out of 10 C. gattii infections, including one infection by a hybrid between C. gattii and C. neoformans. Reflecting the ongoing expansion of C. gattii in geographical zones outside of tropical and subtropical areas like Mediterranean countries, Vancouver Island (British Columbia, Canada) and the Pacific Northwest region (USA), these findings are alarming because of the risk of delayed diagnosis of infections caused by C. gattii. Therefore, the preliminary serological screening for cryptococcal antigen in the case of a suspected Cryptococcus infection should be performed by using an assay with a broad range specificity and sensitivity for C. neoformans and C. gattii, including their hybrids.


Asunto(s)
Antígenos Fúngicos/orina , Criptococosis/diagnóstico , Cryptococcus gattii/inmunología , Pruebas Serológicas/métodos , Adulto , Anciano , Animales , Colombia Británica , Cromatografía de Afinidad/métodos , Cryptococcus neoformans/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , Pruebas de Fijación de Látex/métodos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Estados Unidos
12.
Med Microbiol Immunol ; 203(5): 333-40, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24838744

RESUMEN

Cryptococcosis is a fungal infection mostly caused by Cryptococcus neoformans. We identified agents of cryptococcosis diagnosed in Germany from 2004 to 2010. We used multi-locus sequence typing (MLST) to understand the molecular epidemiology of cryptococcosis. Sero- and mating types of individual patient isolates were determined by PCR. MLST was performed using the seven-locus scheme. Allele and nucleotide diversity was calculated for each locus of C. neoformans var. grubii and C. neoformans var. neoformans. Phylogenetic relations were assessed by dendrograms. Clinical data were compared between infections caused by the two variants. We studied 101 isolates. Eight were identified as hybrids (8%). All non-hybrids were of the α mating type. Among 78 C. neoformans var. grubii (77%), 16 sequence types (STs) were identified including three novel STs. They clustered in four groups, previously isolated in Asia, Europe or worldwide. Among 15 C. neoformans var. neoformans (15%), 10 STs were identified, without clustering. These isolates showed higher allele, and nucleotide diversity compared with C. neoformans var. grubii. C. neoformans var. neoformans was more likely to cause soft-tissue infections (3/9, 33 vs. 1/63, 2%, p = 0.005) and to affect non-AIDS patients (7/14, 50 vs. 15/76, 20%, p = 0.036). C. neoformans var. grubii is the predominant agent of cryptococcosis in Germany. MLST suggests that a part of these cases are acquired abroad by immigrants or tourists. C. neoformans var. neoformans isolates represent a greater genetic diversity and are associated with more variable clinical presentations.


Asunto(s)
Criptococosis/epidemiología , Criptococosis/microbiología , Cryptococcus neoformans/clasificación , Cryptococcus neoformans/genética , Tipificación de Secuencias Multilocus , Técnicas de Tipificación Micológica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Análisis por Conglomerados , Cryptococcus neoformans/aislamiento & purificación , ADN de Hongos/química , ADN de Hongos/genética , Femenino , Genes del Tipo Sexual de los Hongos , Genotipo , Alemania/epidemiología , Humanos , Lactante , Masculino , Persona de Mediana Edad , Epidemiología Molecular , Reacción en Cadena de la Polimerasa , Serotipificación , Adulto Joven
13.
Mycoses ; 57(11): 664-71, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24963815

RESUMEN

In humans, Cryptococcus mainly infects individuals with HIV infection or other types of immunosuppression. Here, we report the first case of disseminated cryptococcosis in a simian immunodeficiency virus-negative 27-year-old female Gorilla gorilla presenting with lethargy, progressive weight loss and productive cough. The diagnosis was confirmed by positive lung biopsy culture, serum cryptococcal antigen, and cerebral histopathology demonstrating encapsulated yeasts. Molecular characterisation of lung culture isolate yielded Cryptococcus neoformans var. grubii. An immune-deficiency could not be demonstrated.


Asunto(s)
Criptococosis/veterinaria , Cryptococcus/aislamiento & purificación , Gorilla gorilla/microbiología , Enfermedades de los Primates/diagnóstico , Animales , Encéfalo/microbiología , Encéfalo/patología , Criptococosis/diagnóstico , Criptococosis/microbiología , Criptococosis/patología , Cryptococcus/fisiología , Femenino , Enfermedades de los Primates/microbiología , Enfermedades de los Primates/patología
14.
Antimicrob Agents Chemother ; 57(8): 3513-7, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23669382

RESUMEN

Since the mid-1990s, a steady increase in the occurrence of itraconazole-resistant Aspergillus fumigatus isolates has been observed in clinical contexts, leading to therapeutic failure in the treatment of aspergillosis. This increase has been predominantly linked to a single allele of the cyp51A gene, termed TR/L98H, which is thought to have arisen through the use of agricultural azoles. Here, we investigated the current epidemiology of triazole-resistant A. fumigatus and underlying cyp51A mutations in clinical samples in Germany. From a total of 527 samples, 17 (3.2%) showed elevated MIC0 values (the lowest concentrations with no visible growth) for at least one of the three substances (itraconazole, voriconazole, and posaconazole) tested. The highest prevalence of resistant isolates was observed in cystic fibrosis patients (5.2%). Among resistant isolates, the TR/L98H mutation in cyp51A was the most prevalent, but isolates with the G54W and M220I substitutions and the novel F219C substitution were also found. The isolate with the G54W substitution was highly resistant to both itraconazole and posaconazole, while all others showed high-level resistance only to itraconazole. For the remaining six isolates, no mutations in cyp51A were found, indicating the presence of other mechanisms. With the exception of the strains carrying the F219C and M220I substitutions, many itraconazole-resistant strains also showed cross-resistance to voriconazole and posaconazole with moderately increased MIC0 values. In conclusion, the prevalence of azole-resistant A. fumigatus in our clinical test set is lower than that previously reported for other countries. Although the TR/L98H mutation frequently occurs among triazole-resistant strains in Germany, it is not the only resistance mechanism present.


Asunto(s)
Antifúngicos/farmacología , Aspergillus fumigatus/efectos de los fármacos , Sistema Enzimático del Citocromo P-450/metabolismo , Farmacorresistencia Fúngica , Proteínas Fúngicas/metabolismo , Itraconazol/farmacología , Alelos , Aspergilosis/epidemiología , Aspergilosis/microbiología , Aspergillus fumigatus/genética , Aspergillus fumigatus/metabolismo , Sistema Enzimático del Citocromo P-450/genética , Proteínas Fúngicas/genética , Alemania/epidemiología , Humanos , Pruebas de Sensibilidad Microbiana , Mutación , Prevalencia , Pirimidinas/farmacología , Triazoles/farmacología , Voriconazol
15.
Emerg Infect Dis ; 18(10): 1618-24, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23017442

RESUMEN

Until recently, Cryptococcus gattii infections occurred mainly in tropical and subtropical climate zones. However, during the past decade, C. gattii infections in humans and animals in Europe have increased. To determine whether the infections in Europe were acquired from an autochthonous source or associated with travel, we used multilocus sequence typing to compare 100 isolates from Europe (57 from 40 human patients, 22 from the environment, and 21 from animals) with 191 isolates from around the world. Of the 57 human patient isolates, 47 (83%) were obtained since 1995. Among the 40 patients, 24 (60%) probably acquired the C. gattii infection outside Europe; the remaining 16 (40%) probably acquired the infection within Europe. Human patient isolates from Mediterranean Europe clustered into a distinct genotype with animal and environmental isolates. These results indicate that reactivation of dormant C. gattii infections can occur many years after the infectious agent was acquired elsewhere.


Asunto(s)
Enfermedades Transmisibles Emergentes/epidemiología , Criptococosis/epidemiología , Cryptococcus gattii/genética , Animales , Enfermedades Transmisibles Emergentes/microbiología , Criptococosis/inmunología , Criptococosis/microbiología , Cryptococcus gattii/clasificación , Cryptococcus gattii/aislamiento & purificación , Europa (Continente)/epidemiología , Genotipo , Humanos , Tipificación de Secuencias Multilocus , Filogenia , Viaje
16.
Mycoses ; 55(5): 426-34, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22248125

RESUMEN

Despite PCR per se being a powerful and sensitive technique, regarding the detection of fungi in patients' blood, no consensus for a standardised PCR protocol yet exists. To complement other ongoing or accomplished studies which tackle this problem, the German Reference Center for Systemic Mycoses conducted an interlaboratory comparison starting with blood samples spiked with fungal cell elements. Altogether, six laboratories using in-house PCR-protocols from Germany and Austria participated in the trial. Blood samples were spiked with vital cells of Candida albicans or Aspergillus fumigatus. Candida was used in the yeast form, whereas Aspergillus cells were either spiked as conidia or as very young germlings, also known as smoo cells. Spiked blood samples contained between 10 and 10 000 cells ml(-1). Depending on the techniques used for fungal cell disruption and DNA-amplification, detection quality was variable between laboratories, but also differed within single laboratories in different trials particularly for samples spiked with less than 100 cells ml(-1). Altogether, at least regarding the detection of A. fumigatus, two of six laboratories showed constant reliable test results also with low fungal cell number spiked samples. Protocols used by these labs do not differ substantially from others. However, as particularities, one protocol included a conventional phenol chloroform extraction during the DNA preparation process and the other included a real time PCR-protocol based on FRET probes. Other laboratory comparisons on the basis of clinical samples should follow to further evaluate the procedures. The difficulties and problems of such trials in general are discussed.


Asunto(s)
Aspergillus fumigatus/aislamiento & purificación , Sangre/microbiología , Candida albicans/aislamiento & purificación , Técnicas de Diagnóstico Molecular/métodos , Micología/métodos , Reacción en Cadena de la Polimerasa/métodos , Austria , ADN de Hongos/aislamiento & purificación , Alemania , Humanos , Cooperación Internacional , Reproducibilidad de los Resultados , Manejo de Especímenes/métodos
18.
Mycoses ; 54(6): e785-8, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21623951

RESUMEN

Mucormycosis is associated with high morbidity and mortality and is perceived as an emerging fungal infection. However, contemporary paediatric data are limited. We present a series of paediatric cases of mucormycosis reported from Germany and Austria collected within a voluntary epidemiological survey through standardised, anonymized case report forms. Twelve cases were reported between January 2004 and December 2008 (six men; mean age: 12.6 years, range: 0.1-17 years). Mucormycosis was proven in nine, and probable in three cases. Isolates included Lichtheimia (syn. Absidia pro parte, Mycocladus) (five), Rhizopus (three) and Mucor (one) species. Infection was limited to soft tissue in three cases, the lung in two cases, and an infected thrombus in one case; rhinocerebral disease was found in three cases, and pulmonary-mediastinal, pulmonary-cerebral and soft tissue-cerebral involvement in one case each. All three patients with isolated soft tissue infection were cured, whereas seven of the remaining patients died (one patient without follow-up). The overall mortality rate was 67%. While these data cannot provide conclusive data on incidence and disease burden of mucormycosis in paediatric patients, they reflect the continuing threat of these infections to immunocompromised patients and the need for improved diagnosis and management.


Asunto(s)
Mucorales/aislamiento & purificación , Mucormicosis/epidemiología , Mucormicosis/microbiología , Adolescente , Austria/epidemiología , Niño , Demografía , Femenino , Alemania/epidemiología , Humanos , Lactante , Masculino , Mucorales/clasificación , Mucormicosis/tratamiento farmacológico , Mucormicosis/patología , Factores de Riesgo , Análisis de Supervivencia , Resultado del Tratamiento
19.
Front Cell Infect Microbiol ; 11: 761596, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-35024355

RESUMEN

Scedosporium spp. are the second most prevalent filamentous fungi after Aspergillus spp. recovered from cystic fibrosis (CF) patients in various regions of the world. Although invasive infection is uncommon prior to lung transplantation, fungal colonization may be a risk factor for invasive disease with attendant high mortality post-transplantation. Abundant in the environment, Scedosporium aurantiacum has emerged as an important fungal pathogen in a range of clinical settings. To investigate the population genetic structure of S. aurantiacum, a MultiLocus Sequence Typing (MLST) scheme was developed, screening 24 genetic loci for polymorphisms on a tester strain set. The six most polymorphic loci were selected to form the S. aurantiacum MLST scheme: actin (ACT), calmodulin (CAL), elongation factor-1α (EF1α), RNA polymerase subunit II (RPB2), manganese superoxide dismutase (SOD2), and ß-tubulin (TUB). Among 188 global clinical, veterinary, and environmental strains, 5 to 18 variable sites per locus were revealed, resulting in 8 to 23 alleles per locus. MLST analysis observed a markedly high genetic diversity, reflected by 159 unique sequence types. Network analysis revealed a separation between Australian and non-Australian strains. Phylogenetic analysis showed two major clusters, indicating correlation with geographic origin. Linkage disequilibrium analysis revealed evidence of recombination. There was no clustering according to the source of the strains: clinical, veterinary, or environmental. The high diversity, especially amongst the Australian strains, suggests that S. aurantiacum may have originated within the Australian continent and was subsequently dispersed to other regions, as shown by the close phylogenetic relationships between some of the Australian sequence types and those found in other parts of the world. The MLST data are accessible at http://mlst.mycologylab.org. This is a joined publication of the ISHAM/ECMM working groups on "Scedosporium/Pseudallescheria Infections" and "Fungal Respiratory Infections in Cystic Fibrosis".


Asunto(s)
Scedosporium , Australia/epidemiología , Variación Genética , Humanos , Tipificación de Secuencias Multilocus , Filogenia , Polimorfismo Genético , Scedosporium/genética
20.
J Gen Virol ; 91(Pt 2): 580-9, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19864502

RESUMEN

Effective disinfectants are of key importance for the safe handling and reprocessing of surgical instruments. This study tested whether new formulations containing SDS, NaOH and 1-propanol (n-propanol) are simultaneously active against a broad range of pathogens including bacteria, fungi, non-enveloped viruses and prions. Inactivation and disinfection were examined in suspension and on carriers, using coagulated blood or brain homogenate as an organic contaminant. Coomassie blue staining was used to assess whether the formulations undesirably fixed proteins to rough surfaces. A mixture of 0.2 % SDS and 0.3 % NaOH in 20 % n-propanol achieved potent decontamination of steel carriers contaminated with PrP(TSE), the biochemical marker for prion infectivity, from 263K scrapie hamsters or from patients with sporadic or variant Creutzfeldt-Jakob disease. 263K scrapie infectivity on carriers was decreased by > or =5.5 logs. Furthermore, the formulation effectively inactivated poliovirus, hepatitis A virus and caliciviruses (including murine norovirus) in suspension tests. It also yielded significant titre reductions of bacteria (Enterococcus faecium, Mycobacterium avium; >6 logs), fungi (spores of Aspergillus niger; > or =5 logs) and poliovirus (>4 logs) embedded in coagulated blood on carriers. The formulation was not found to fix proteins more than was observed with water as the cleaning reagent. In conclusion, SDS, NaOH and n-propanol can synergistically achieve fast, broad-range disinfection.


Asunto(s)
Bacterias/efectos de los fármacos , Desinfectantes/metabolismo , Desinfectantes/farmacología , Desinfección/métodos , Hongos/efectos de los fármacos , Priones/efectos de los fármacos , Virus/efectos de los fármacos , Animales , Humanos , Viabilidad Microbiana/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA